Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased to $-0.03 in the quarter versus EPS of $-0.20 in the year-earlier quarter. Revenue Decreased 38.58% to $19.9 million from the year-earlier quarter.
Isis Pharmaceuticals, Inc. reported adjusted EPS loss of $0.03 per share. By that measure, the company beat the mean analyst estimate of $-0.23. It beat the average revenue estimate of $15.78 million.